Genes help explain GLP‑1 drug response
Researchers found common genetic variants that help explain why people respond differently to GLP‑1 weight‑loss drugs — in other words, your DNA can partly predict both benefit and side effects. These results come from a pair of papers in Nature and coverage explains the findings don’t tell the whole story but do suggest genetics will shape who benefits and who is more likely to feel nausea. That shift matters because it creates roles that sit between big‑data analysis and patient care — people who build the prediction models and clinicians who interpret them for patients. (nature.com, scientificamerican.com)
Glucagon-like peptide 1 drugs work by copying a gut hormone your body already uses after you eat, which slows stomach emptying and tells the brain you’ve had enough. Semaglutide copies that signal, and tirzepatide copies it plus a second gut signal called gastric inhibitory polypeptide. (nature.com) That helps explain why two people can take the same weekly shot and get very different results. In the new Nature study, researchers looked at 27,885 people who reported using glucagon-like peptide 1 medicines and asked whether common DNA differences tracked with extra weight loss or more nausea and vomiting. (nature.com) The main hit was in a gene called glucagon-like peptide 1 receptor, which is the molecular “lock” these drugs are designed to open. People carrying one version of that gene lost about 0.76 kilograms, or 1.6 pounds, more per copy of the variant than non-carriers. (nature.com) A second signal showed up in side effects. Variants in the glucagon-like peptide 1 receptor gene were linked to nausea or vomiting, and variants in the gastric inhibitory polypeptide receptor gene were also linked to nausea or vomiting in people taking tirzepatide, which targets both receptors. (nature.com) The useful part is not that one gene “decides” whether a drug works. The useful part is that the strongest variants sit in the exact genes the drugs are built to hit, which makes the biology look less like a statistical fluke and more like a real mechanism. (nature.com, nature.com) The catch is size. Outside experts told the Science Media Centre that the extra weight loss tied to the top variant is small next to the usual 10% to 15% weight loss seen with these medicines, and factors like sex, dose, drug choice, and treatment length still explain more of the difference between patients. (sciencemediacentre.org) The data also came with limits that matter in medicine. Much of the study used self-reported weight and side effects from 23andMe participants, and one expert noted that self-reported weight loss in the paper was much larger than weight loss seen in linked electronic health records, about 11.8% versus 5.8%. (sciencemediacentre.org) So this does not mean a cheek swab can already tell you whether Wegovy or Zepbound will be perfect for you. It means researchers now have proof that common variants in the drug-target pathway can improve prediction models that combine DNA with ordinary clinical facts. (statnews.com, nature.com) That is the part likely to change clinics first. Someone has to build those risk models from large genetic datasets, and someone else has to explain to a patient why a result might mean “slightly better odds of weight loss” or “higher odds of nausea,” not a guarantee either way. (scientificamerican.com, nature.com) The bigger shift is that obesity medicine is starting to look more like oncology, where doctors already use tumor genetics to choose treatments. These new papers do not get glucagon-like peptide 1 drugs all the way there, but they move the field from “some people just respond differently” to named receptors, measured variants, and testable predictions. (scientificamerican.com, nature.com)
